Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer.
Precision medicine through liquid biopsy represents an emerging approach in the management of cancer. The CTC count in blood samples from patients with advanced breast cancer is a powerful prognostic factor for both progression free and overall survival. Moreover, high levels of CTCs at any time during the treatment can reliably predict progression before imaging studies and/or tumor markers. Furthermore, there are works on the molecular characterization of the CTCs and their potential ability to guide the treatment in a dynamic way. However, their role remains controversial. Detection and enumeration of CTCs is variable among different tumors and is subjected to biases related mainly to their methodology, which is not completely standardized. In addition, they must demonstrate their clinical value to guide the treatment and a translation on patient's survival.
['Cueva Bañuelos|Juan F|JF|', 'Rodríguez López|Carmela|C|', 'Cortegoso Mosquera|Alexandra|A|', 'Palacios Ozores|Patricia|P|', 'Curiel García|Teresa|T|']
D014408:Biomarkers, Tumor D001943:Breast Neoplasms D018450:Disease Progression D006801:Humans D000073890:Liquid Biopsy D009360:Neoplastic Cells, Circulating D015996:Survival Rate
Circulating tumor cells (CTCs) Metastatic breast cancer Precision oncology Prognostic value Treatment monitoring